CAMPBELL, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced the results of a randomized trial (NCT04408586) evaluating the effect of QSYMIA® (phentermine and topiramate extended-release capsules CIV) in combination with DELI compared to DELI plus placebo on weight loss and cardiovascular disease risk outcom ...